Author: anomaly

Invex Therapeutics makes progress ahead of IIH EVOLVE phase three clinical trial

Invex Therapeutics receives tax rebate for neurological drug research

Small Caps – Invex Therapeutics chases global registration of Presendin to treat idiopathic intracranial hypertension

Invex Therapeutics reports busy quarter in Presendin development

Small Caps – Invex Therapeutics signs major collaboration with Peptron

Invex Therapeutics closes busy quarter of development on Presendin for idiopathic intracranial hypertension

Invex Therapeutics receives US FDA feedback on planned Presendin trial targeting idiopathic intracranial hypertension

Small Caps – Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder

COVID-19 Impact on IIH – J Neurol article by Prof Alex Sinclair

JAMA Ophthalmology Publication – Alex Sinclair